Evaluación de la utilización de una consulta de diagnóstico rápido de cáncer de pulmón. Tiempos de demora diagnóstica y terapéutica

Heredia, Javier Hueto Pérez de; Rivas, Pilar Cebollero; Rodrigo, José Antonio Cascante; Vela, Isabel Andrade; Martínez, I. Pascal; Mitjans, Joan Boldú; Astibia, Víctor Manuel Eguía

doi:10.1016/j.arbres.2012.03.009

Cited by 9 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, at this time in Europe there are no LC screening recommendations though The European Society of Radiology and the European Respiratory Society recommend screening within a clinical trial or in routine clinical practice at certified medical centres6. Instead, the strategy implemented in many European hospitals to achieve an early detection is the acceleration in the time to diagnosis in the so called Rapid Diagnostic Units for LC1011121516. Consequently, we intended to design a marker-based classification algorithm to be used in these Units, where the priority is to detect all LC cases (high sensitivity), in order to select those patients that should be immediately submitted to more invasive tests.…”

Section: Discussionmentioning

confidence: 99%

“…In Spain, the reduction of the time before diagnosis and staging is a priority8101112, since both radiological imaging (CT, PET) and invasive procedures for histological confirmation (bronchoscopy, thoracic needle aspiration or thoracentesis) are required in the diagnostic work-up of a LC patient1314. Rapid or Quick Diagnostic Units (RDU/QDU) have been established within the public health system, with the main objective of accelerating the early diagnosis of potentially severe diseases such as cancer, avoiding hospitalisations for purely diagnostic purposes, minimizing hospital-related morbidity, reducing costs, and improving patient satisfaction1516.…”

mentioning

confidence: 99%

“…Rapid or Quick Diagnostic Units (RDU/QDU) have been established within the public health system, with the main objective of accelerating the early diagnosis of potentially severe diseases such as cancer, avoiding hospitalisations for purely diagnostic purposes, minimizing hospital-related morbidity, reducing costs, and improving patient satisfaction1516. In Spain approximately 40–50% of the patients attending LC-RDUs display non-cancerous lung pathologies1112. Consequently, clinical decision-making in the setting of LC-RDU would benefit from non-invasive markers that could help predict LC risk in symptomatic individuals, discerning cancerous patients who should be submitted to confirmatory diagnostic procedures from those without cancer in whom a conservative approach could be applied avoiding initially such procedures.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units

Blanco-Prieto

Chiara

Rodríguez-Girondo

et al. 2017

Sci Rep

View full text Add to dashboard Cite

While evidence for lung cancer screening implementation in Europe is awaited, Rapid Diagnostic Units have been established in many hospitals to accelerate the early diagnosis of lung cancer. We seek to develop an algorithm to detect lung cancer in a symptomatic population attending such unit, based on a sensitive serum marker panel. Serum concentrations of Epidermal Growth Factor, sCD26, Calprotectin, Matrix Metalloproteinases −1, −7, −9, CEA and CYFRA 21.1 were determined in 140 patients with respiratory symptoms (lung cancer and controls with/without benign pathology). Logistic Lasso regression was performed to derive a lung cancer prediction model, and the resulting algorithm was tested in a validation set. A classification rule based on EGF, sCD26, Calprotectin and CEA was established, able to reasonably discriminate lung cancer with 97% sensitivity and 43% specificity in the training set, and 91.7% sensitivity and 45.4% specificity in the validation set. Overall, the panel identified with high sensitivity stage I non-small cell lung cancer (94.7%) and 100% small-cell lung cancers. Our study provides a sensitive 4-marker classification algorithm for lung cancer detection to aid in the management of suspicious lung cancer patients in the context of Rapid Diagnostic Units.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units

Blanco-Prieto

Chiara

Rodríguez-Girondo

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Kaplan-Meier survival estimates were used to determine the five-year lung cancer-specific survival for all patients, and the log-rank (Mantel-Cox method) and Breslow (generalized Wilcoxon) analyses were used to compare the differences between factors. The cutoff values were chosen based on medical literature regarding delayed treatment in lung cancer 10 - 12 . Survival was calculated from the date of patient admission to our institution to the date of the last follow-up or until death from any cause.…”

Section: Methodsmentioning

confidence: 99%

Impact of the delay to start treatment in patients with lung cancer treated in a densely populated area of Brazil

Abrão¹,

Abreu²,

Rocha³

et al. 2017

Clinics

View full text Add to dashboard Cite

OBJECTIVES:The aim of this study is to evaluate the access of patients with lung cancer in a densely populated area of São Paulo to the Brazilian Public Health System, focusing on the time spent from symptom onset or initial diagnosis until the beginning of treatment.METHODS:We retrospectively reviewed 509 patients with malignant lung neoplasms who were admitted to a single reference oncology center of the public health system between July 2008 and December 2014. Patients were considered eligible for this study if they were older than 18 years and had not undergone any previous oncology treatment when they were admitted to the institution. The following data were collected from all patients: age, gender, smoking status, tumor staging, time from the when the first symptoms were experienced by the patient to when the patient was diagnosed with cancer, time from the first appointment to cancer diagnosis, and time from when the patient was diagnosed with cancer to the initiation of treatment.RESULTS:The median time from symptom onset to diagnosis was three months. From the first appointment to diagnosis, the median time interval was one month; however, 79% of patients were diagnosed in up to two months. The median time from diagnosis to the start of treatment was one month, but most patients (82.5%) started treatment in up to two months.CONCLUSION:In our highly populated region with preferential access to the public health system, patients are required to wait a relatively long time to effectively begin treatment for lung cancer. This type of study is important to alert medical societies and government health agencies.

show abstract

“…[ 2 – 4 ] The 5-year survival rate of LC patients is less than 15%. [ 5 , 6 ] Early diagnosis is key for the survival of LC patients. Unfortunately, symptoms in early LC are mild, even without any discomfort.…”

Section: Introductionmentioning

confidence: 99%

SIRT3 acts as a novel biomarker for the diagnosis of lung cancer

Feng¹,

Gu²,

Li³

et al. 2021

Medicine

View full text Add to dashboard Cite

Lung cancer (LC) is a prevalent malignancy worldwide with increased morbidity and mortality. Mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase sirtuin-3 (SIRT3) has been reported to be involved in tumorigenesis. In this retrospective study, we measured the expression and diagnostic value of SIRT3 in LC patients. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to measure serum SIRT3 mRNA level in 150 LC patients and 52 healthy volunteers. SIRT3 protein level was detected using western blot for 84 pairs of LC and adjacent normal tissues. The association of SIRT3 mRNA level with clinical parameters of LC patients was estimated via chi-square test. Receiver operating characteristic curve (ROC) was plotted to evaluate the diagnostic performance of serum SIRT3 in LC patients. SIRT3 mRNA and protein levels were significantly decreased in LC tissues and serum samples, compared with corresponding controls ( P < .05). Moreover, the expression of SIRT3 mRNA was negatively associated with tumor size ( P = .002), tumor node metastasis stage ( P < .001), and metastasis ( P < .001). ROC curve demonstrated that serum SIRT3 could distinguish LC patients from healthy individuals, with an area under the curve of 0.918. The optimal cutoff value was 3.12, reaching a sensitivity of 86.4%, and a specificity of 94%. SIRT3 expression is significantly down-regulated in LC serum and tissues. SIRT3 may be employed as a promising biomarker in the early diagnosis of LC.

show abstract

Evaluación de la utilización de una consulta de diagnóstico rápido de cáncer de pulmón. Tiempos de demora diagnóstica y terapéutica

Cited by 9 publications

References 20 publications

Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units

Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units

Impact of the delay to start treatment in patients with lung cancer treated in a densely populated area of Brazil

SIRT3 acts as a novel biomarker for the diagnosis of lung cancer

Contact Info

Product

Resources

About